MagicMed Industries to present at KCSA Strategic Communications' Psychedelic-Focused Investor Event

January 21, 2021

MagicMed: Bringing the Drug Candidate Library Model to Psychedelics

January 20, 2021

MagicMed Psilocybin Derivatives Program Announced

January 6, 2021

2020: A Year In Review for Psychedelic Pioneer MagicMed Industries

December 31, 2020

MagicMed Attracts Investors to Advance Library of Psychedelic Derivatives

December 23, 2020

How Will Psychedelics Become Medicine? A Scientific Review of the Drug Development Pathway

December 23, 2020

MagicMed Targets Massive Market with Pharmaceutical Derivatives Program

December 23, 2020

MagicMed Completes Patent Portfolio of their Psybrary while Launching Candidate Selection Program

December 22, 2020

Innovation Pays Off in Psychedelics

December 18, 2020

MagicMed Aims to Mainstream Psychedelic Therapy with World’s Largest ‘Psybrary’

December 1, 2020

How Can Synthesizing and Improving Psilocybin, as well as Other Psychedelics, Lead to Better Mental Health Treatments?

November 25, 2020

MagicMed Shortcuts Commercialization Timeline with University Agreement

November 4, 2020

Pioneering Psychedelic Company MagicMed Forms Strategic Research Partnership With University of Calgary

November 3, 2020

Calgary Scientists Buzzing over Magic Mushroom-Inspired Medical Research

November 1, 2020

MagicMed Industries Signs Deal with the University of Calgary to Accelerate Psybrary Development

October 30, 2020

MagicMed Makes Psychedelic Molecules to turn Trips into Treatments

October 30, 2020

Just How Big is the Psychedelics Opportunity?

October 27, 2020

3 Psychedelic Business Models (and What’s Best for Investors)

October 22, 2020

MagicMed CSO, Dr. Peter Facchini, Speaks with Psychedelic Finance

October 14, 2020

Proactive ONE2ONE Virtual Investor Forum , Investing in Psychedelics, The Path to Big Pharma Webinar

October 7, 2020

3 Key Leadership Traits for Disruptive Psychedelic Drug Development

October 5, 2020

How the Psybrary™ Could Revolutionize Psychedelic Drug Discovery

September 28, 2020

MagicMed CEO talks the past, present, and most importantly the future of Psychedelics

September 24, 2020

3 Key Takeaways from MagicMed Industries Presentation at Psychedelic Capital

September 14, 2020

MagicMed Industries completes oversubscribed financial raise bringing in 1.6 million

September 2, 2020

MagicMed Raises $1.6M to Launch Psychedelic Drug Discovery Platform

September 2, 2020

3 Major Industry Verticals in the Medicalization and Prescriptibility of Psychedelic Medicine

August 27, 2020

From “Plant to Pill”: How the MagicMed Psybrary Is Poised to Revolutionize Psychedelic Drug Development

August 25, 2020

Why You Should Invest in Psychedelic ‘Platform Plays’

August 25, 2020

Dr. Joseph Tucker | Founder & CEO, MagicMed Industries

August 24, 2020

Mushrooms to Pills: How Psychedelic Drugs Will Come to Market

August 11, 2020

MagicMed Sets Out to Help Partners Develop Pharma-Grade Psychedelics

July 22, 2020

MagicMed Industries bring a fresh and unique approach to development of Psilocybin Derivatives

July 17, 2020